阴道黄体酮用于早产临产停止后延长妊娠:一项随机临床试验
这项在以色列3所大学附属医学中心开展的随机临床试验(2018年12月19日至2023年2月27日)纳入129例24周0天至34周0天经保胎治疗后早产临产停止的单胎和双胎妊娠妇女,随机接受阴道微粒化黄体酮200 mg每日两次或不治疗至36周6天。主要终点为入组至分娩的平均天数和37周前自发性早产率。结果显示两组妊娠延长天数(40.0 vs 37.4天,P=.44)和自发性早产率(25% vs 30%;RR 0.8;95%CI 0.5-1.5;P=.52)均无差异。双胎妊娠亚组中黄体酮延长妊娠(43.7 vs 26.1天,P=.02)、推迟分娩孕周(36.5 vs 34.7周,P=.01)、缩短新生儿重症监护病房住院时间(4.9 vs 13.2天,P=.03)和总住院时间(8.3 vs 15.1天,P=.03)、提高出生体重(2444 vs 2018 g,P=.01)。作者认为黄体酮不是延长妊娠或预防自发性早产的有效治疗,但双胎妊娠中显示有益效果,需进一步研究。
要点
- 早产临产停止后每日阴道微粒化黄体酮400 mg(200 mg每日两次)至36周6天,未能延长妊娠(40.0 vs 37.4天,P=.44)或降低37周前自发性早产率(25% vs 30%;RR 0.8;95%CI 0.5-1.5;P=.52)。
- 双胎妊娠亚组中,黄体酮组较不治疗组妊娠延长(43.7 vs 26.1天,P=.02)、分娩孕周推迟(36.5 vs 34.7周,P=.01)。
- 双胎妊娠亚组中,黄体酮组新生儿重症监护病房住院时间缩短(4.9 vs 13.2天,P=.03)、总住院时间缩短(8.3 vs 15.1天,P=.03)、出生体重更高(2444 vs 2018 g,P=.01)。
- 作者认为早产临产停止后阴道微粒化黄体酮200 mg每日两次不是延长妊娠或预防自发性早产的有效治疗,但双胎妊娠中的有益效果需进一步研究。
适用人群与场景
- 纳入单胎和双胎妊娠、24周0天至34周0天经保胎治疗后早产临产停止的妇女。
- 排除有早产史或本次妊娠无症状性宫颈缩短的妇女。
处置流程与药物剂量
- 阴道微粒化黄体酮200 mg每日两次(每日总量400 mg),直至36周6天妊娠。
- 对照组不接受治疗。
研究设计与关键结果
- 随机临床试验,纳入129例参与者(黄体酮组65例,不治疗组64例),平均(SD)年龄27.6(5.1)岁。
- 主要终点:入组至分娩平均天数黄体酮组40.0(17.8)天 vs 不治疗组37.4(20.3)天,P=.44;37周前自发性早产率16例(25%)vs 19例(30%),相对风险0.8(95%CI 0.5-1.5),P=.52。
- 双胎妊娠亚组(黄体酮组12对,不治疗组15对):妊娠延长43.7(18.1)天 vs 26.1(15.2)天,P=.02;分娩孕周36.5(1.4)周 vs 34.7(2.2)周,P=.01;新生儿重症监护病房住院时间4.9(10.6)天 vs 13.2(18.5)天,P=.03;总住院时间8.3(9.6)天 vs 15.1(17.2)天,P=.03;出生体重2444(528)g vs 2018(430)g,P=.01。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为早产临产停止后阴道微粒化黄体酮200 mg每日两次不是延长妊娠或预防自发性早产的有效治疗。
- 作者认为双胎妊娠中黄体酮显示有益效果,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Women with arrested preterm labor (APTL) are at very high risk for spontaneous preterm delivery (SPTD), the leading cause of neonatal mortality and morbidity. To date, no maintenance therapy has been found to be effective for pregnancy prolongation. A few clinical trials with considerable methodological limitations have demonstrated some efficacy for 400 mg vaginal micronized progesterone (VMP) in women with APTL.
OBJECTIVE: To investigate the effectiveness of daily 400 mg VMP for the prolongation of pregnancy after APTL.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted between December 19, 2018, and February 27, 2023, in 3 university-affiliated medical centers in Israel. Participants included women with singleton and twin pregnancies after APTL following tocolysis at 24 weeks 0 days to 34 weeks 0 days' gestation. Women with a history of preterm delivery or asymptomatic cervical shortening in the current pregnancy were excluded.
INTERVENTIONS: Participants were randomly allocated to receive VMP 200 mg twice a day or no treatment until 36 weeks 6 days' gestation.
MAIN OUTCOMES AND MEASURES: The primary end points were mean number of days from study enrollment to delivery and the rate of SPTD prior to 37 weeks' gestation.
RESULTS: A total of 129 participants were enrolled (65 in the VMP group and 64 in the no-treatment group). Mean (SD) age was 27.6 (5.1) years. Between the VMP and no-treatment groups, there was no difference in pregnancy prolongation (mean [SD], 40.0 [17.8] vs 37.4 [20.3] days; P = .44) and the rate of SPTD (16 [25%] vs 19 [30%]; relative risk, 0.8; 95% CI, 0.5-1.5; P = .52). In twin pregnancies, including 12 and 15 pairs in the VMP and no-treatment groups, respectively, VMP prolonged pregnancy (mean [SD], 43.7 [18.1] vs 26.1 [15.2] days; P = .02), postponed the delivery week (36.5 [1.4] vs 34.7 [2.2] weeks; P = .01), shortened the length of stay in the neonatal intensive care unit (4.9 [10.6] vs 13.2 [18.5] days; P = .03) and overall hospital stay (8.3 [9.6] vs 15.1 [17.2] days; P = .03), and was associated with a higher birth weight (2444 [528] vs 2018 [430] g; P = .01).
CONCLUSIONS AND RELEVANCE: These findings show that VMP given in a dosage of 200 mg twice a day following APTL is not an effective treatment to prolong pregnancy or prevent SPTD. However, VMP demonstrated beneficial effects in twin pregnancies, warranting further investigation.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02430233.
参考来源
- Nachum Z, Ganor Paz Y, Massalha M, et al. Vaginal Progesterone for Pregnancy Prolongation After Arrested Preterm Labor: A Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38976270. doi:10.1001/jamanetworkopen.2024.19894
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。